Home Blog Page 449

Youhug Media Hosts “Radiant Vision of Chinese Content” 2026 New Series Gala: Unveiling a Blockbuster Slate and Pioneering AI Drama Strategy

HONG KONG, March 23, 2026 /PRNewswire/ — Youhug Media recently concluded its prestigious “Radiant Vision: Youhug 2026 New Series Gala” in Hong Kong. During the event, the company unveiled an ambitious release slate featuring highly anticipated titles such as Blossoms of Power, Rebirth, The Awakening, Ctrl+Alt+Life, Confessions, The Road to Splendor, and Have it All. Beyond its diverse lineup of TV and film projects, Youhug Media officially announced a groundbreaking strategic roadmap for AI-generated drama series, demonstrating its vision and commitment to content innovation and industrial evolution. The gala saw the appearance of lead actors and creative teams who shared insights into their latest works, while official trailers and posters were released simultaneously online, garnering significant attention from industry professionals and audiences alike.


A Diverse Slate of Premium Productions Captivates the Industry

Themed “Radiant Vision,” the gala showcased a massive array of upcoming projects. Distinguished guests in attendance included Li Xiaojun, Director of the Sichuan Provincial Radio and Television Bureau; Zhang Hai, Deputy Director of the Sichuan Provincial Radio and Television Bureau; Xu Jingyi, Head of the TV Drama Division of the Shanghai Municipal Administration of Culture and Tourism; Chi Xiaoling, Second-level Investigator of the Radio, TV, and Online Audio-Visual Program Division of the Shanghai Municipal Administration; and Lu Jian, Chief Representative of the Hong Kong Trade Development Council in East China.

Lu Chao, President of Youhug Media, delivered an opening address outlining the company’s future strategy. He emphasized that “elevating quality is the ultimate weapon against change,” and pledged to “actively embrace AI empowerment to better tell Chinese stories”.

The project showcase kicked off with Blossoms of Power, starring Meng Ziyi and He Yu. The teaser’s tense score and powerful performances highlighted a world of undercurrents, where Eastern aesthetics meet a complex game of power, emotion, and destiny. This was followed by the hot-blooded period epic Rebirth, starring Li Yunrui, Huang Yang Tiantian, and Zhang Kangle. The series follows the journey of Zhuge Yue (Li Yunrui) and Chu Qiao (Huang Yang Tiantian) as they survive the Battle of the Icy Lake to bring peace to the world.

Ranging from Eastern aesthetic power struggles to hot-blooded ensemble epics, the latest slate from Youhug Media showcases a vast array of genres and distinct styles, designed to comprehensively meet the diverse preferences and high expectations of global audiences. Furthermore, Youhug Media remains steadfast in its commitment to a diversified strategic roadmap for film and television development.

Youhug’s 2026 lineup further expands into diverse genres:

  • The Awakening: A hardcore revenge action drama starring Zhang Kangle as a prisoner who endured trials in Heiyuan Prison from a young age. He escapes to Wangcheng to avenge his father, where he befriends Qi Jun (Zhou Jieqiong) and becomes entangled in the power struggles between the Yihesheng gang and the city’s rulers.
  • Ctrl+Alt+Life: This annual hot-blooded growth drama stars Zeng Shunxi, Zhang Kangle, Liu Xiening, and Jiang Lai. The story follows an accidental identity swap between two young men—one shedding his halo to rediscover his passion, while the other rises to the top of the competitive arena—offering a profound reflection on the choices and destinies of youth.
  • Confessions: This highly anticipated psychological thriller reunites the creative team behind The Pig, The Snake, and The Pigeon, starring Ethan Juan, Gingle Wang, and Yi-wen Chen. The narrative begins with a 2004 bombing and kidnapping case in Taipei that entwines three innocent families in a 20-year cycle of intergenerational conflict. Utilizing a highly stylized audiovisual language, the series explores the abyss of human nature and fissures in human nature through themes of high-stakes revenge and psychological fractures.
  • The Road to Splendor: Directed by Deng Ke and written by Nan Zhen, this period road movie stars Ding Yuxi and Deng Enxi. Moving beyond traditional domestic settings, the series uses a novel Eastern aesthetic to portray the survival and mutual redemption of salt merchant Zhao Ling and fallen noble daughter Fu Tingyun as they navigate a chaotic world.

Pioneering the AI Frontier and Future IP Ecosystem

Beyond the key upcoming projects for 2026, several projects currently in development were officially announced during the gala, showcasing a vast array of genres and unique creative highlights. Among them, the period legend Have it All (Yi Shou Zhai Xing Yi Shou Chui Di), which blends Eastern classical charm with contemporary significance, was heavily announced. Starring Meng Ziyi, the series follows the journey of Princess Regent Xiao Qitang as she navigates through conspiracies, eventually rewriting her destiny with wisdom and integrity in a high-energy plot filled with constant reversals.

Additionally, the new urban romance Ai,Love (Ai De Suan Fa) released an all-AI-produced concept teaser. Moving beyond a singular romantic narrative, the series explores the dilemmas of intimacy through the lens of three urban couples, serving as a “Contemporary Urban Emotional Survival Guide.” Also unveiled was Mo Yu Ji , a high-quality production blending time travel, romance, power struggles, and light comedy, which tells a story of choice, persistence, and redemption amidst chaotic times. Furthermore, the uniquely charming new work Hong Bai Xi Shi was officially announced, using a comedic shell to explore themes of life and death, encouraging audiences to regain the courage to love and be loved.

Following the enthusiastic response to the series MOBIUS (Bu Mian Ri), a newly upgraded film adaptation is also in preparation, aiming to innovate while maintaining the core charm of the original IP. The gala also featured The Annoyance of The Gods IP, based on the blockbuster work by Ma Boyong, which will reshape the legend of Journey to the West from a fresh perspective. Other new projects announced to further enrich Youhug Media’s content layout include Jin Li Yue Long Men, Da Jiang Ben Liu, Ran Yu, and Panda (Da Xiong Mao). Notably, the drama Under the Table (Tai Di), focusing on the stakes of human nature, also garnered significant attention for its potential to provide a brand-new viewing experience.

As a leading domestic film and television content creation company, Youhug Media has long been dedicated to premium drama creation and industrial production systems. During the gala, Youhug officially announced the establishment of its AICG Lab, marking its formal entry into the AI drama series track and its commitment to empowering more AI creators. The event featured the premiere of Qin Ling Qing Tong Gui Shi Lu, a fantasy suspense short drama created through a full-chain AI process. Based on the teaser, the project demonstrates high levels of completion and aesthetic value in its world-building, character performance, and atmospheric rendering, showcasing the refreshing advantages of AI tools.

Simultaneously, the two lead characters, Qin Lingyue and Lin Xiyan, were officially “signed” as Youhug’s first AI Actors. Youhug stated that while AI technology currently shortens production cycles and reveals new possibilities for deep integration with film and television creation, it remains in an exploratory stage. The company emphasized that real emotional resonance is paramount; the performances of human actors are irreplaceable and will become increasingly precious. Consequently, AI actors will only appear in AI-specific dramas and will not be used in live-action series.

By expanding from upcoming titles to AI-driven creations, Youhug Media has formed a full-category content ecosystem where long-form dramas, films, short plays, and AI series develop synergistically across genres such as period, reality, suspense, and action. The company remains committed to building an industry benchmark that balances artistic strength with market competitiveness, delivering works with depth, warmth, and value to contribute to the high-quality development of the industry.

“It Survived 40,000 Feet, Drier Than the Sahara”–The Ultimate K-Beauty Barrier Cream Just Landed on Amazon

The evolution of a 10-year R&D heritage that previously swept top US luxury department stores. Meet Dr.BRID C, the next-generation biotech skincare line launching on Amazon—all under $25.

NEW YORK and SEOUL, South Korea, March 23, 2026 /PRNewswire/ — Altitude 40,000 feet. Humidity below 20%. If you’ve ever looked in the mirror after a long-haul flight to find your skin rough, red, and completely parched, this new beauty brand’s origin story will instantly resonate with you.

Dr.BRID C, the next-generation biotech skincare line launching on Amazon
Dr.BRID C, the next-generation biotech skincare line launching on Amazon

Born out of the desperate need for VIPs and beauty professionals to protect their skin in harsh, Sahara-like cabin environments, the next-generation biotech K-beauty brand Dr.BRID C has officially launched on US Amazon.

The ‘Paradox of Beauty’: How We’re Destroying Our Own Skin
Even on the ground, our skin is under daily attack as if it were 40,000 feet in the air. Air conditioning, pollution, and ironically, our daily beauty routines—heavy makeup, harsh double-cleansing, and chemical exfoliation—are slowly stripping away our skin barrier.

To break this vicious cycle, Dr.BRID C goes beyond temporary fixes with a clear and uncompromising philosophy: “Defense Before Beauty.”

Luxury Skincare Science That Awakens ‘C-Peptide’
Dr.BRID C’s barrier-repairing prowess is rooted in a 10-year R&D heritage that previously dominated luxury US department stores like Barneys New York.

Rejecting conventional moisturizers that just suffocate the skin with heavy oils, their scientists developed a proprietary patented technology: PEPTIBRID®. This technology encapsulates a powerful collagen-signaling peptide in soothing zinc oxide, delivering it safely and deeply into the skin. In cell tests, this resulted in a massive 175.3% surge in ‘C-peptide,’ a key biomarker for new collagen synthesis.

“When trying to create a cream that could help skin survive a 14-hour flight, we realized surface hydration simply wasn’t enough,” says the Lead Researcher at Dr.BRID C. “Dr.BRID C helps build the fundamental strength skin needs to breathe and defend itself in any extreme environment.”

“Balanced and Springy”—Real Customers Prove the Barrier Miracle
Dr.BRID C focuses on rebuilding the skin’s core rather than just offering a temporary band-aid. And real customer reviews are already proving the miracle.

An Amazon reviewer who suffered from a compromised oil-water balance and tightness praised the texture and moisture retention: “This cream moisturizer is smooth and makes the skin feel soft after overnight wear without lingering filminess or discomfort. Skin does not feel greasy or oily but balanced and springy.”

Furthermore, testers who experienced extreme inner dryness from frequent travel and UV exposure testified to the overwhelming difference: “I have sensitive skin, so after traveling, UV exposure makes my skin reactive and dry… This feels like I’ve finally found the right cream. It spreads smoothly and absorbs quickly without leaving residue. It addresses inner dryness beautifully.”

The #40,000ft Cream Lineup: A Customized Barrier Trio (All Under $25)
Driven by the “Defense Before Beauty” philosophy, the launch centers around three targeted #40,000ft Creams designed for specific skin conditions.

  • #40,000ft Barrier Defense Basic Cream ($19.99): The absolute hero of the lineup. Formulated with an optimal 12ppm of PEPTIBRID®, this cream becomes your new daily shield if your oil-water balance has collapsed. It absorbs instantly without any greasiness, creating the perfect velvet canvas for your makeup to grip onto.
  • #40,000ft Hydro Relief Cream ($21.99): A cooling gel-cream packed with a high concentration of 21ppm PEPTIBRID® for sensitized, dehydrated skin. Just one use blocks Trans-Epidermal Water Loss (TEWL) by 30.81%, delivering an instant hit of deep hydration.
  • #40,000ft Intensive Moisture Basic Cream ($21.99): The ultimate age-defying density care. Boasting 22ppm of PEPTIBRID®—the highest concentration in the lineup—it goes beyond barrier support to visibly improve signs of aging like enlarged pores, rough texture, and eye wrinkles over 8 weeks.

Rounding out the collection is a synergistic, clean-formula lineup—including a pH-balancing toner and a 100-hour moisture-locking serum—all priced under $25. If you’re ready to experience cutting-edge barrier defense that survives even the harshest conditions, Dr.BRID C is available now on Amazon(https://www.amazon.com/drbridc?maas=maas_adg_EE29DA495FDC3C85E3F4533006833714_afap_abs&ref_=aa_maas&tag=maas).

 

WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO

  • Revenue increased by 46.7% YoY to RMB 5,944 million
  • Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024
  • Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percentage points increase compared to 2024(excluding net interest income and exchange impact)
  • The total global customer base expanded to over 640 companies, and 14 out of the TOP 20 global pharmaceutical companies have partnered with us
  • The total number of iCMC projects reached to 252, with 70 newly signed iCMC projects
  • The robust PPQ pipeline: Secured 18 PPQ projects with 10 new PPQ projects added in 2025
  • The total backlog grew to US$1.49 billion, representing a strong 50.3% YoY growth
  • Winner of “Best CDMO” and “Best CRO” Awards: Three consecutive “Best CDMO” Awards from 2023 to 2025 at World ADC Awards, and “Best CRO” Awards at 2025 World ADC Awards

SHANGHAI, March 23, 2026 /PRNewswire/ — WuXi XDC Cayman Inc. (the “WuXi XDC” or the “Group”, stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2025 (the “Reporting Period”).

Management Discussion on 2025 Annual Results and Recent Events (Jan to March 2026)

  • Rapid Growth – As a leading player in the thriving, innovative global bioconjugates industry, the Group has maintained its rapid business growth by providing world-class bioconjugates CRDMO integrated services and empowering its global partners to accelerate and transform ADC and broader bioconjugate development.
  • Strategic M&A – Beyond strong operational results, we advanced two strategic M&A initiatives that elevated our extensive capabilities and expanded our global footprint, enabling us to better serve the global customers. (including the Suzhou site from the acquisition of BioDlink, and the Hefei site acquisition)
  • Technology Engine – Breakthrough advancements across our WuXiDARx™, X-LinC, and WuXiTecan-1 & WuXiTecan-2 platforms are accelerating the development of next-generation bioconjugates, positioning us at the forefront of innovation and drive value creation.
  • Recent Events To further advance our evolving growth strategy and strengthen our next phase of expansion, we continue to scale and innovate across our payload-linkers platform.
    • Jiangyin site: we have planned a new manufacturing facility as our Jiangyin site. This strategic investment establishes scalable production capabilities for emerging novel payload-linkers, including dual-payloads, AOC, and as well as the PPQ batches supply for late-stage projects. 5x the volume of payload-linker production compared to current level at Wuxi site
    • Technology platform-driven value creation: We have invested consistently in R&D innovation to unlock potential value. In February, we entered into a new flagship strategic collaboration with Earendil Labs, to out-licensing our proprietary WuXiTecan-2, with total potential consideration of up to US$885 million, including upfront, milestone and royalty payments.

Financial Highlights for Annual Results of 2025

Revenue

The Group’s revenue increased by 46.7% YoY to RMB 5,944 million for the year ended December 31, 2025. This increase was primarily attributable to (i) the growth in the number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group’s established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group’s projects into later stages.

Gross Profit and Its Margin

The Group’s gross profit increased by 72.5% YoY to RMB 2,139 million, with a gross profit margin of  36.0% for the year ended December 31, 2025, and a 5.4 percentage points increase compared to that of 2024. This improvement is driven by (i) the enhanced overall operation and manufacturing efficiency, (ii) the utilization ratio of production facilities continued to improve, mainly due to strong customer demand, and (iii) the successful ramp-up of operating production lines including BCM2 L2 and DP3.

Adjusted Net Profit and Its Margin

The Group’s adjusted net profit increased by 69.9% YoY to RMB 1,559 million, demonstrating the strong profit growth momentum of the Group’s core operating business. The margin of adjusted net profit was 26.2% for the year ended December 31, 2025, and a 3.6 percentage points increase compared to that of 2024.

Customers and Projects Highlights for Annual Results of 2025

  • We have continuously expanded our customer base, reaching a cumulative total of 643, through strong customer-enabling empowerment.
  • The “Enable, Follow, and Win the Molecule” strategy continued to drive sustained and rapid project growth. The total number of integrated projects (“iCMC projects”) is 252, with a record 70 newly signed integrated projects.
  • The Group has successfully secured over 18 PPQ projects, with 10 new PPQ projects added in 2025.
  • The Group has a diversified project base covering both innovative ADC and broader bioconjugate (“XDC”) projects. The total number of integrated ADC projects reached 226, and the number of integrated XDC projects increased to 26.
  • In 2025, the Group explored over 5,600 molecules of multiple modalities, including bispecific ADCs, dual-payload ADCs, degrader-antibody conjugates (DAC), antibody-oligonucleotide conjugates (AOC), antibody-peptide conjugates (APC), lysosome-targeting chimaeras (LYTAC), etc.

Fully Integrated R&D Technology Platform for Annual Results of 2025

The Group strives to empower customers with cutting-edge conjugation and payload-linker technologies, along with extensive expertise in bioconjugate development capabilities to fulfill diverse R&D requirements.

WuXiDARx™

  • The proprietary WuXiDARx™ technology aims to meet customers’ demands for highly homogeneous ADCs with a wide range of DAR values at clinically validated conjugation sites.
  • WuXiDARx™ technology enables dual-payload ADC generation via native interchain cysteine sites without antibody engineering or enzymatic conjugation, offering a streamlined, cost-effective single-platform solution.
  • The platform has successfully facilitated customers to bring 8 ADC pipelines from preclinical stage to clinical stage.
  • WuXiDAR2™ offers narrow DAR distribution with a simple process; WuXiDAR1™ combines the process of WuXiDAR2™ with thiol-rebridging connector to produce homogeneous DAR1 which could be potentially developed in AOCs/APCs.

X-LinC

  • The proprietary X-LinC technology could potentially enhancing ADC stability and therapeutic window since the data demonstrated that it significantly improves plasma stability by replacing the maleimide connector.

WuXiTecan

  • The Group is developing its proprietary payload and hydrophilic linker to enable ADCs with better stability, hydrophilicity, and tolerability.
  • The newly launched WuXiTecan-1 and WuXiTecan-2 platforms have demonstrated excellent efficacy and safety profiles in preclinical studies. Notably, WuXiTecan-2 based dual-payload (MMAE+WuXiTecan-2) ADC achieved enhanced anti-tumor efficacy in CDX model.
  • Customers are actively evaluating the performance of WuXiTecan‑1 and WuXiTecan‑2, with potential collaborations under discussion involving our proprietary payloads featuring novel mechanisms of action and multi‑payload platform.

Capacity Expansion & Business Operation Updates for Annual Results of 2025

  • The total number of full-time employees increased to 2,662 in the Group, driven by rapid business growth and the Group’s capacity expansion.
  • All the Group’s manufacturing operations are conducted in accordance with the GMP regulations set by the FDA, EMA, and NMPA. The Group has completed over 200 GMP audits from global customers, including 20 audits by EU Qualified Persons.
    • Wuxi site: Further increased its integrated manufacturing capacities. The DP5 and DP6 facility in Wuxi is currently under construction.
    • Singapore site: On track to begin GMP release in 2026 1H, driven by solid overseas customer demand. This state-of-the-art site expands our global manufacturing footprint and reinforces our “China + Singapore” dual sourcing strategy, delivering enhanced supply security and operational agility for customers worldwide.
    • Shanghai site: Further investments in the discovery and technology frontier as global R&D center.
  • Executed two strategic acquisitions aligned with core growth objectives, significantly strengthening manufacturing and R&D capabilities:
    • Suzhou site: the acquisition of BioDlink further enhances our integrated bioconjugate production covering mAb, DS and DP, and expands our customer base and project pipelines.
    • Hefei site: the acquisition expands our expertise in peptide and oligonucleotide synthesis, enabling accelerated development of novel conjugates.
  • The Group was named the winner of “Best CDMO” for the third consecutive year in 2023, 2024 and 2025, as well as “Best CRO” at the 2025 World ADC Awards.
  • The Group also received multiple awards from the 2025 Extel ranking in diverse categories, signifying our commitment to high-quality corporate governance and investor interactions.
  • The Group is committed to strengthen ESG governance and received top-tier ratings in ESG rankings, reflecting our exceptional performance in corporate responsibility, risk management, and ethical business conduct.

CEO Comment

Dr. Jimmy Li, CEO of WuXi XDC, stated, “2025 was a transformative year for WuXi XDC, as we solidified our leadership in global biconjugate CRDMO market and completed several key strategic initiatives: we expanded our production capacity footprint through ‘organic expansion + strategic acquisition’ and established our Singapore site, which is expected to achieve GMP release in the first half of 2026, building a truly global supply chain system. Recently, we also entered into a technology licensing partnership for WuXiTecan-2, helping our clients accelerate bioconjugates development and realize the value resonance of our proprietary technology platforms. Looking ahead to 2026, we will continue to uphold our unwavering commitment to innovation, operational excellence, and collaboration with our clients. We will empower our customers with continuous evolution, bring breakthrough therapies to more patients worldwide, and lead the development of the industry.”

Key Financials Ratios (For the Year Ended December 31)

Key Financials (RMB Mn)

2025

2024

YoY%

Revenue

[5,944]

4,052

[46.7%]

Gross Profit 

[2,139]

1,240

[72.5%]

Margin (%)

[36.9%]

30.6 %

Adjusted Net Profit 

[1,559]

917

[69.9%]

Margin (%)

[26.2%]

22.6 %

About WuXi XDC

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and manufacturing services for ADC and broader bioconjugates. For more information about WuXi XDC, please visit: www.wuxixdc.com 

Contacts

Investor: wuxixdc.ir@wuxibiologics.com
Media: wuxixdc_pr@wuxibiologics.com
BD: wuxixdc_info@wuxibiologics.com

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our customers’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

The Group defines “adjusted net profit attributable to owners of the Company” as net profit attributable to owners of the Company after elimination of share-based compensation expense as non-cash expenditure, net foreign exchange loss or gain as non-operating item, non-recurring/one-off transaction costs as non-operating item, and net of interest income and finance costs as non-operating item. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

 

Hotel Linen Manufacturer HANBI Optimizes Hotel ROI with 30% More Durable, High-Hygiene Bedding

By integrating factory-direct manufacturing and skin-friendly safety standards, HANBI delivers high-durability hotel bedding solutions that stabilize procurement budgets for 2,000+ luxury hospitality brands globally.

NANNING, CHINA, March 23, 2026 /PRNewswire/ — For decades, the global hospitality conversation has been dominated by mattress “hardware” from giants like Sealy and Simmons. But a critical shift is happening in the “software” of sleep: the hotel linens that define a guest’s direct tactile experience. HANBI, a vertically integrated hotel linen manufacturer, today announced the global expansion of its high-performance hotel bedding solutions. By addressing the industry’s chronic struggle with textile longevity, HANBI’s new line promises to extend product lifespan by 30%, offering a strategic edge to hotel owners worldwide.

HANBI delivers factory-direct bedding solutions that combine high-performance durability with the soft, tactile elegance demanded by the world's leading hospitality groups.
HANBI delivers factory-direct bedding solutions that combine high-performance durability with the soft, tactile elegance demanded by the world’s leading hospitality groups.

In an era of rising inflation, HANBI is redefining hotel ROI. The company controls the entire supply chain from raw yarn to the final product. By merging large-scale R&D with a “Factory-to-Hotel” direct model, it helps global hospitality partners—including Howard Johnson and Accord Hotels—reduce procurement overhead by 5% to 10%.

Engineered for Longevity: The 30% Advantage
The primary drain on a hotel’s linen budget is the rapid deterioration caused by industrial laundering. HANBI has neutralized this via its proprietary reinforced weaving technology. This ensures that every hotel bedding set maintains its structure, whiteness, and “first-day” feel for up to 30% longer than standard industry alternatives.

“We don’t just weave fabric; we engineer performance for the modern hotel linen factory,” says a spokesperson for HANBI. “Our linens undergo rigorous pre-shrinking and high-temperature setting. This ensures that a HANBI bed sheet retains its crisp, white, ‘first-day’ aesthetic, which is essential for any hotel luxury bedding standard. For a hotel owner, that 30% extra life is pure profit.”

Professional Hygiene Standards in a Luxury Setting
Post-pandemic travelers demand more than just comfort; they demand uncompromising hygiene. HANBI’s unique advantage lies in its dual-track production: applying the same strict hygiene standards found in their hospital bed sheets to their commercial hotel towels and linens. All core products are manufactured under strict safety standards, guaranteeing they are skin-friendly and free from harmful irritants. This remains a critical benchmark for eco-conscious wholesale hotel supplies.

One-Stop Integration: From Hotel Pillows to Amenities
HANBI’s “One-Stop” philosophy simplifies the fragmented procurement process. Their integrated catalog covers every guest touchpoint:

  • Hotel Bedding & Sets: High-thread-count cotton with superior breathability and durability.
  • Hotel Towels & Bathrobes: High-GSM, long-staple cotton for maximum absorbency and softness.
  • Guest Room Accessories: From hotel pillows to ergonomic slippers and bespoke amenity kits that align with a brand’s unique DNA.

Market Validation & Global Reach
Late shipments are a constant headache for hotel managers. HANBI avoids this drama by maintaining a 98% on-time delivery rate. This consistency explains why 90% of their clients have stuck with the company for three years or more. Beyond just shipping products, HANBI acts as an agile OEM and ODM partner. This gives boutique owners and global giants the power to prototype a signature look and scale it across properties without the usual lead-time headaches or budget creep.

About HANBI
HANBI is a leading vertically integrated hotel linen manufacturer specializing in professional hospitality textiles. Unlike traditional trading companies, HANBI operates its own state-of-the-art hotel linen factory, ensuring total control over quality, cost, and lead times. From premium hotel linens to sustainable fabrics meeting the rigorous hygiene standards, HANBI is the “invisible champion” supporting the world’s most demanding hospitality brands.

For more information, please visit: https://www.hanbi-hotelsupplies.com/

Media Contact:
Company Name: Guangxi Hanbi Textile Co., Ltd.
Telephone: 0771-5585836
Email: sammi@hanbitextile.com
WhatsApp: +86 15878178593

Frost & Sullivan Warns Invasive AI Agents Could Undermine Mobile Ecosystem Trust and Global Competitiveness

New white paper calls for dual-authorization governance framework as AI agents reshape mobile value chains

SHENZHEN, China, March 23, 2026 /PRNewswire/ — According to Frost & Sullivan’s new analysis, White Paper on the Governance of Invasive Agents 2026, the rapid evolution of AI agent technology from proof-of-concept to large-scale deployment is beginning to disrupt the foundational trust mechanisms of the mobile internet ecosystem.

System-Level Agents Reshape Control and Value Distribution

As AI agents increasingly become the primary interface for user interaction, traditional mobile applications risk being relegated to execution layers rather than points of engagement. Activities such as search, comparison, and transaction initiation are progressively shifting upstream to the agent layer – reducing direct user interaction with applications and weakening established monetization models.

Frost & Sullivan analysis suggests that if invasive agents reach a 25% user penetration rate, the commercial value of utility applications could decline by up to 39%, while content and social platforms may see reductions of approximately 19.5%, and transactional applications around 15.4%.

Rising Governance, Cost, and Security Pressures

Rather than creating significant new market value, invasive agents are expected to drive a redistribution of existing traffic and revenues – intensifying competition within the ecosystem. Application developers may be forced to respond with increased investment in security, interface adjustments, and anti-automation measures.

At the same time, the concentration of high-level system permissions within a single agent environment amplifies systemic risk. Potential vulnerabilities – including prompt injection attacks and unintended automated actions – could result in privacy breaches, financial loss, and broader ecosystem instability.

Frost & Sullivan estimates that at a 25% penetration level, mobile application development costs could increase by approximately 16%, while overall ecosystem governance costs may rise by more than 34%.

Call for a Trusted Governance Framework

To ensure sustainable growth, Frost & Sullivan emphasizes the need for a governance model built on dual authorization and full-chain auditability. Under this framework, AI agents must obtain not only user consent for system-level permissions but also explicit authorization from application providers for executing underlying business actions.

AI agents represent a significant step forward in digital interaction models, but their long-term success depends on trust, transparency, and accountability. A governance framework grounded in dual authorization and auditability will be critical to balancing innovation with ecosystem stability and user protection.

Trust as a Prerequisite for Global AI Competitiveness

Frost & Sullivan notes that global competition in AI is no longer defined solely by technological capability or deployment speed. Governance capacity, trust infrastructure, and alignment with international standards are emerging as critical differentiators.

For China’s AI industry, the report highlights that pursuing rapid expansion at the expense of trust could limit international collaboration opportunities and undermine long-term global credibility. Conversely, a governance approach rooted in security, interoperability, and accountability will be essential to sustaining global competitiveness.

To access the full White Paper on the Governance of Invasive Agents 2026 and explore how organizations can navigate the evolving AI agent landscape, click here.

About Frost & Sullivan

Frost & Sullivan, the Growth Pipeline Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritize, and execute transformational growth strategies.

Your Transformational Growth Journey Starts Here: Schedule Your Growth Pipeline Dialog™ with the Frost & Sullivan team.

Contact:
Rachel Zhang
Frost & Sullivan China
E: rachel.zhang@frostchina.com
T: +86 021-3209-6800

Olight and Tesla Owners of Silicon Valley Spotlight the ArkPro for Spring Break Travel Safety

SHENZHEN, China, March 23, 2026 /PRNewswire/ — As Spring Break travel surges across the United States, more drivers are preparing for longer road trips, remote stops, and unpredictable situations on the road. From nighttime charging to roadside emergencies, travel today requires a new level of readiness—especially after dark.

To explore these real-world scenarios, Olight has partnered with Tesla Owners of Silicon Valley to highlight how compact, versatile, and high-performance lighting tools like the ArkPro are becoming essential for modern travel safety.

Olight x Tesla Owners of Silicon Valley
Olight x Tesla Owners of Silicon Valley

A New Essential for Modern Travel

The ArkPro is designed not just as a flashlight, but as a compact safety and readiness tool for travelers. With four integrated light sources and seven lighting modes, a magnetic hands-free design, and a portable form factor, it supports a wide range of real-world scenarios, from roadside inspections to campsite setup, where reliable visibility is essential.

Insights from Evolving Travel Habits

Insights from the Tesla owner community reinforce a broader trend: drivers are placing greater importance on preparedness as travel becomes more flexible and unpredictable. From late-night stops to unfamiliar surroundings, dependable lighting is increasingly viewed as a necessity rather than an accessory.

The Tesla Owners of Silicon Valley vice president shared how the ArkPro Ultra has already become part of his routine: “My wife and I walk every night, and having a reliable flashlight is a must—whether spotting wildlife or crossing dark streets where drivers aren’t always paying attention. The ArkPro Ultra’s bright beam and compact design have replaced our bulkier flashlight entirely.”

His experience highlights how versatile lighting tools are evolving from optional gear into everyday essentials—whether for neighborhood walks or Spring Break road trips.

From Convenience to Preparedness

Lighting tools are no longer viewed as optional accessories, but as essential components of everyday preparedness. Whether during a planned road trip or an unexpected stop, reliable visibility can directly impact safety and decision-making. The ArkPro reflects this shift—bridging everyday carry with travel readiness and delivering dependable illumination when it matters most.

To mark the season, Olight is launching a limited-time Spring Break campaign to engage its community and highlight evolving travel needs. For more product information, please visit the official website.

About Olight

Founded in 2007, Olight is a global innovator in portable lighting, offering high-tech solutions for everyday carry, outdoor, tactical, and professional use. With over 1,200 product patents and international recognitions, including the prestigious iF Design Award and Red Dot Design Award, Olight reaches users in over 100 countries worldwide.

 

NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, March 23, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

KPMG recently released an AI at work survey.

Ashley Mastronardi delivers the pre-market update on March 23rd

  • Stocks jump and oil retreats after President Donald Trump postpones strikes on Iran energy targets with ceasefire talks beginning.
  • Alto Neuroscience CFO Nick Smith will join NYSE Live to discuss the company’s $120 million in private placement financing to help advance its mission of matching patients with the right psychiatric medications.
  • An executive from KPMG will join NYSE Live to share the results of a new survey that looks at how employees are using AI in the workplace.
  • The RSAC Conference, focusing on cybersecurity innovation and AI-driven defense, kicks off today from San Francisco.

For market insights, IPO activity, and today’s opening bell, download the NYSE TV app at tv.nyse.com

Opening Bell
Copa Airlines (NYSE: CPA) celebrates 20th listing anniversary.

Closing Bell
Jacobs (NYSE: J) hosts global executive leadership team meeting for 180 leaders in Midtown and visiting the NYSE.

Click here to download the NYSE TV App

Guardian Medal Resources at the NYSE on March 20.
Guardian Medal Resources at the NYSE on March 20.

 

 

Alibaba International Launches Accio Work, an Enterprise AI Agent for Global Businesses

Accelerating Agentic Business: A proactive enterprise-grade AI Agent team built for secure global operations

NEW YORK, March 23, 2026 /PRNewswire/ — Alibaba International unveiled Accio Work, a plug-and-play enterprise AI agent that equips businesses with an immediate, no-code taskforce. Requiring zero setup, the platform deploys specialized agents to execute complex, long-horizon operations from day one, signaling a significant shift toward “Agentic Business”—a new era where AI moves beyond passive Q&A tools to become active, autonomous executors.

First introduced in November 2024 as an AI-powered B2B sourcing engine, Accio has since rapidly evolved into a full-scale AI agent, now serving over 10 million monthly active users globally. The launch of Accio Work marks a new phase in this evolution—moving beyond sourcing to a full-scale enterprise AI agent designed to support the diverse operational needs of SMEs worldwide.

“Our vision is to democratize enterprise-grade AI,” said Kuo Zhang, President of Alibaba.com and VP of Alibaba International. “We want every entrepreneur—regardless of team size—to access an intelligent workforce that operates with the scale of a major corporation. Small businesses will find Accio Work especially useful.”

A Proactive, Ready-to-Use “Agent Team”

For non-technical entrepreneurs, building a custom AI workforce usually means navigating complex engineering and risky deployments. Accio Work removes these barriers with a pre-configured team of agents designed for the entire SME lifecycle—from initial market analysis, design, and sourcing to long-term store optimization and inventory monitoring.

Its secret lies in dynamic orchestration: upon receiving a goal, the system instantly assembles a cross-functional “squad” of specialized agents – analysts, creators, logistics experts – to work in parallel.

Beyond handling long-term operations, the agent team proactively provides strategic insights and suggestions. This enables SMEs and solo founders to run end-to-end global commerce workflows with enterprise-grade precision, requiring no code or setup.

Autonomous Execution and Global Connectivity

Accio Work enables entrepreneurs to run online businesses or physical stores with a new level of automation, specifically designed to alleviate the heavy operational burden faced by SMEs. Users can deploy a customizable fleet of AI agents to handle critical tasks, including:

  • Automated Compliance: Managing real-time VAT filings, tax refunds, and customs documentation across more than 100 markets.
  • Autonomous Sourcing: Executing Request for Quotations (RFQs) and conducting multi-round negotiations with suppliers to secure optimal terms.
  • Operational Integration: Driving marketing automation and overseeing logistics through tools like Telegram and WhatsApp.

Additionally, Accio Work allows users to encapsulate their unique processes into reusable “skills,” enabling them to standardize, share, or even monetize their expertise.

Alibaba Ecosystem-Driven Reliability and Security

Built on Alibaba Group’s proprietary ecosystem, Accio Work is structurally engineered to minimize AI hallucinations. Unlike models reliant on general knowledge prone to inaccuracies, Accio Work draws directly from real-time consumer trends and actual business transaction records across Alibaba’s e-commerce platforms. This foundation ensures every output is specific, accurate, and commercially relevant.

Recognizing the sensitivity of delegating critical tasks to AI, Accio Work employs a security-first approach featuring sandboxed environments and granular permission management. High stakes actions involving finances or file access require explicit user approval, ensuring the AI operates strictly within defined boundaries. Furthermore, the system respects data sovereignty, allowing users to choose not to save any data on servers.

Accio Work will be available on www.Accio.com by the end of March.

About Alibaba International

Alibaba International Digital Commerce Group (Alibaba International) is dedicated to supporting the development of global digital trade with AI-powered technology. It operates various platforms with distinctive business models, covering multiple countries and regions around the world.